Trials / Recruiting
RecruitingNCT07309822
Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.
Observational Prospective Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 27 (estimated)
- Sponsor
- Probelte Pharma S.L.U. · Industry
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltaven® With Apis mellifera, Polistes dominula or Vespula spp. allergic patients
Detailed description
This prospective open multi-centre non-interventional study assess the safety and effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltaven in Apis mellifera, Polistes dominula or Vespula spp (children and adults) in routine medical care.
Conditions
Timeline
- Start date
- 2025-02-01
- Primary completion
- 2031-05-01
- Completion
- 2031-12-01
- First posted
- 2025-12-30
- Last updated
- 2025-12-30
Locations
13 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT07309822. Inclusion in this directory is not an endorsement.